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Abstract
Background: Low total testosterone (TT) and sex hormone-binding globulin (SHBG) concentrations have been associated
with the metabolic syndrome (MetS) in men, but the reported strength of association varies considerably.
Objectives: We aimed to investigate whether associations differ across specific subgroups (according to age and body mass
index (BMI)) and individual MetS components.
Data sources: Two previously published meta-analyses including an updated systematic search in PubMed and EMBASE.
Study Eligibility Criteria: Cross-sectional or prospective observational studies with data on TT and/or SHBG concentrations
in combination with MetS in men.
Methods:We conducted an individual participant data meta-analysis of 20 observational studies. Mixed effects models were
used to assess cross-sectional and prospective associations of TT, SHBG and free testosterone (FT) with MetS and its
individual components. Multivariable adjusted odds ratios (ORs) and hazard ratios (HRs) were calculated and effect
modification by age and BMI was studied.
Results: Men with low concentrations of TT, SHBG or FT were more likely to have prevalent MetS (ORs per quartile decrease
were 1.69 (95% CI 1.60-1.77), 1.73 (95% CI 1.62-1.85) and 1.46 (95% CI 1.36-1.57) for TT, SHBG and FT, respectively) and
incident MetS (HRs per quartile decrease were 1.25 (95% CI 1.16-1.36), 1.44 (95% 1.30-1.60) and 1.14 (95% 1.01-1.28) for TT,
SHBG and FT, respectively). Overall, the magnitude of associations was largest in non-overweight men and varied across
individual components: stronger associations were observed with hypertriglyceridemia, abdominal obesity and
hyperglycaemia and associations were weakest for hypertension.
Conclusions: Associations of testosterone and SHBG with MetS vary according to BMI and individual MetS components.
These findings provide further insights into the pathophysiological mechanisms linking low testosterone and SHBG
concentrations to cardiometabolic risk.
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e100409
Citation: Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen T-P, et al. (2014) Testosterone, Sex Hormone-Binding Globulin and the Metabolic Syndrome in
Men: An Individual Participant Data Meta-Analysis of Observational Studies. PLoS ONE 9(7): e100409. doi:10.1371/journal.pone.0100409
Editor: Andrea Cignarella, University of Padova, Italy
Received August 2, 2013; Accepted May 28, 2014; Published July 14, 2014
Copyright:  2014 Brand et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have the following interests: Prof. Jukka T. Salonen is currently employed by MAS-Metabolic Analytical Services Oy. This
employment commenced after the completion of this study. There are no patents, products in development or marketed products to declare. This does not alter
the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* Email: y.t.vanderschouw@umcutrecht.nl
{ Deceased.
Introduction
The metabolic syndrome (MetS) affects approximately 25% of
the adult population [1] and its prevalence is increasing worldwide
[2–4]. MetS is associated with a twofold increase in cardiovascular
disease (CVD) risk and a nearly fivefold increased risk of type 2
diabetes [5,6]. Given its major public health impact, there is an
urgent need for a better understanding of the underlying
mechanisms of MetS, in particular factors driving and influencing
its pathophysiology.
A large number of epidemiological studies have linked low
concentrations of total testosterone (TT) and its carrier protein, sex
hormone-binding globulin (SHBG), to MetS in men [7–15].
Despite the clear link between testosterone, SHBG and MetS, the
exact nature of the observed associations remains uncertain, given
the high variability in the strength of associations reported. This
between-study heterogeneity can be partially explained by
incomparability in study design (i.e. with regard to MetS criteria,
hormone assays and sample size), but also by differences in
population structure. Recent evidence suggests that associations
may differ according to age and BMI, as stronger associations have
been reported in young [12] and nonobese [14] men. Strength of
associations may also vary across individual MetS components.
Cross-sectionally, stronger associations have been reported for
abdominal obesity and hypertriglyceridemia [7-9,16], but con-
flicting data exist for other MetS components [7–9,16] and no
studies so far have examined these associations prospectively.
We previously re-examined the observational data on testoster-
one, SHBG and MetS in a literature-based meta-analysis [17], but
analyses for specific subgroups and MetS components were
hampered by the absence of individual data. In addition,
individual studies were largely heterogeneous with regard to MetS
criteria and methods used for free testosterone (FT) estimation and
confounder adjustment. To conduct a more comprehensive and
powerful assessment of the associations of testosterone and SHBG
with MetS, we pooled the original raw data of observational
studies. Such a meta-analysis of individual participant data
provides a unique opportunity to 1) examine associations of
testosterone and SHBG with MetS in a uniform way; 2) produce
estimates for specific subgroups according to age and body mass
index (BMI) and 3) determine specific MetS components through
which associations with testosterone and SHBG are primarily
mediated. In this article, we present the findings of this
collaborative project.
Methods
Identification of studies
Studies were eligible for inclusion if they had data on TT and/
or SHBG in combination with MetS in men using a cross-sectional
or prospective design. Most studies were identified in previously
published meta-analyses [17,18]; additional studies were identified
following an updated systematic search in PubMed and EMBASE
(using the key words ‘metabolic syndrome’, ‘insulin resistance
syndrome’ and ‘syndrome X’ combined with ‘testosterone’, ‘sex
hormone-binding globulin’, ‘SHBG’, ‘androgens’, ‘sex hormones’
and ‘sex steroids’), hand searching of relevant journals and
correspondence with collaborating investigators. For details on the
study selection procedure (and flow diagram) we refer to our
literature-based meta-analysis [17], as the same approach was used
for the current analysis. Thirty-three eligible studies were
identified, and communication was established with the authors
of 24 studies. From these studies, four declined and 20 agreed to
participate. All studies used a cross-sectional design and four
studies also collected outcome data prospectively. All studies were
previously published and had each received local institutional
review board approvals as well as consent from participants (figure
S1).
Data collection
A study protocol was sent out to all collaborators including
information on study organisation, objectives, data transfer and
checking. Collaborators were asked to provide data on the
following variables for each individual: waist circumference,
systolic and diastolic blood pressure, high-density lipoprotein
(HDL) cholesterol, triglycerides, glucose, TT and SHBG concen-
trations, age at recruitment, use of hormonal therapy, timing of
blood sample collection and details of any overnight fast, assay
methods and length of follow-up for prospective data. If available,
data were also collected on ethnicity, smoking status, alcohol
consumption, physical activity, BMI, insulin concentration, history
of CVD, type 2 diabetes and hypertension.
The original data were checked for completeness and possible
inconsistencies using the original publications. For most studies,
the data provided were identical to those analysed and published
previously. In the TARF (Turkish Adult Risk Factor) [19], SHIP
(Study of Health in Pomerania) [12] and DETECT (Diabetes
Cardiovascular Risk-Evaluation: Targets and Essential Data for
Commitment of Treatment) [20,21] cohorts additional prospective
data were available that were not included in their previously
published reports.
Data processing & measures
Blood samples were mostly collected in the morning after an
overnight fast. In SHIP [12] samples were collected in a non-
fasting state throughout the day. In DETECT [20,21] ,40% of
the samples were non-fasting. Not all studies performed SHBG
measurements, and various assays were used for the measurement
of TT and SHBG (for a full description of the assay methods and
samples used for the hormone analyses, see Table S1). When both
Testosterone, SHBG and Metabolic Syndrome in Men
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TT and SHBG were provided, FT concentrations were calculated
using the equation of Vermeulen et al. [22] assuming a fixed
albumin concentration of 43 g/L. We recoded categorical
variables on alcohol consumption (drinker vs. non-drinker),
cigarette smoking (current smoker vs. non-smoker) and physical
activity (active vs. inactive) to maximize comparability across
studies. When both glucose and insulin concentrations were
provided, the homeostasis model assessment for insulin resistance
(HOMA-IR) was calculated using the formula HOMA-IR =
(fasting insulin in mIU/L x fasting glucose in mmol/L)/22.5.
Values of HOMA-IR were not normally distributed and
transformed logarithmically prior to analysis.
MetS was defined according to the most recent harmonized
definition presented in the 2009 Joint Scientific Statement [23],
using ethnic-specific cut-offs for abdominal obesity. Men were
considered to have MetS if they had $3 of the following
components: 1. abdominal obesity (waist circumference $102 cm
for Caucasian men and waist circumference $90 cm for Asian
men); 2. hypertriglyceridemia (triglycerides $1.7 mmol/L); 3. low
HDL-cholesterol (HDL-cholesterol ,1.03 mmol/L), 4. hypergly-
caemia (fasting blood glucose $5.6 mmol/L); 5. hypertension
(systolic blood pressure $130 mm Hg or diastolic blood pressure
$85 mm Hg). Men taking antihypertensive medication were
considered having high blood pressure and those with type 2
diabetes were counted as having hyperglycaemia. We slightly
modified the criteria for men having non-fasting blood samples
(using a blood glucose cut-off of $8.0 mmol/L and triglyceride
cut-off of $2.3 mmol/L) [24].
Statistical analyses
Analyses were restricted to men aged 18 years and older not
using hormonal therapy (N=14,025). We excluded men with
missing data on individual MetS components (N=1,186). We
further removed extreme outliers .4 standard deviations (SD)
from the mean for measured TT, SHBG, and calculated FT
concentrations (N=28), leaving 12,811 men with complete data
on TT and 9,525 men with complete data on SHBG and FT,
respectively. Sex hormone concentrations were categorized into
quartiles using cut-off points determined separately for cross-
sectional and prospective data.
We first examined the associations between sex hormones and
prevalent MetS. To account for between-study heterogeneity and
within study correlation, we used mixed effects logistic regression
models (i.e. generalized linear mixed-effects models (GLMM) with
logit link function) including a random intercept for study. In these
models, odds ratios (ORs) and 95% confidence intervals (95% CIs)
were estimated using the Laplace approximation [25]. Next, we
studied the associations of sex hormones with incident MetS. For
these analyses, we excluded all individuals with MetS at baseline.
We used shared frailty models with random effects at the study
level to estimate hazard ratios (HRs) and 95% CIs. The shared
frailty model is an extension of the Cox proportional hazards
model and accounts for within study correlation by incorporating
shared random effects. We performed linear trend analysis by
entering quartiles as a continuous term into the model. We also
estimated ORs and HRs per quartile decrease of TT, SHBG and
FT to provide a summary measure of association.
To investigate the influence of potential confounders, we
calculated age-adjusted and multivariable-adjusted ORs and
HRs including age and lifestyle factors (smoking status, alcohol
consumption and physical activity). In a next step, we additionally
adjusted the analyses for BMI and HOMA-IR to examine whether
associations between sex hormones and MetS were independent of
body composition and insulin resistance. To investigate whether
associations of TT with MetS were influenced by SHBG, we
additionally adjusted for SHBG in a separate analysis. We tested
for effect modification by age and BMI by including interaction
terms using the Wald-test. If a significant interaction was found,
we stratified the analyses for age (,40 years, 40–60 years, .60
years) and BMI (,25 kg/m2, 25–30 kg/m2,$30 kg/m2). We also
performed a series of sensitivity analyses. First, we excluded men
with prevalent type 2 diabetes (diagnosed diabetes or fasting blood
glucose $7 mmol/L) and CVD at baseline. To investigate the
influence of potential selection bias, we also repeated the analyses
including population-based samples only. Next, we excluded men
with non-fasting blood samples to examine the impact of
measurement errors due to fasting state. To assess the impact of
other methodological differences between studies, we also repeated
the analyses using study-specific quartiles of TT, SHBG and FT.
Finally, we examined associations with each MetS component
separately. We did this analysis for both prevalent and incident
MetS components. For the latter, we studied incidence of
individual components after excluding men with the respective
component at baseline. We used linear mixed effects models to
estimate multivariable-adjusted means of TT, SHBG and FT
across categories of MetS components (0, 1, 2, and $3).
All statistical analyses were performed using STATA version
11.1 (Stata Corp., College Station, TX, USA).
Results
Table 1 summarizes the participant characteristics for each
individual study. All men had complete data on age and history of
type 2 diabetes. Nineteen studies had recorded data on BMI, 13
studies had data on insulin concentrations and CVD history and 9
studies collected data on all lifestyle factors. Absolute sex hormone
concentrations varied across individual studies: variations for TT,
SHBG, and FT were 1.6-fold, 2.0-fold and 2.2-fold respectively
(Table S1).
Associations between sex hormones and prevalent MetS
The overall prevalence of MetS was 27.9% (N=3,574). An
inverse relation was observed between TT, SHBG, FT, and MetS
(Table 2). Men with low TT concentrations were more likely to
have prevalent MetS compared to men with high TT concentra-
tions (OR per quartile decrease = 1.70 (95% CI 1.63-1.77)).
Associations were similar for SHBG (OR per quartile decrease
= 1.75 (95% CI 1.66-1.84)), but weaker for FT (OR per quartile
decrease = 1.40 (95% CI 1.32-1.47)). Adjustment for lifestyle
factors did not materially change the ORs. Associations were
attenuated after adjustment for BMI and HOMA-IR, but
remained statistically significant (Table 2). The association
between TT and MetS weakened, but persisted after adjusting
for SHBG (OR per quartile decrease of TT =1.48 (95% CI 1.37-
1.59)).
Results from models including interaction terms are shown in
Table 3. The association between SHBG and MetS was modified
by BMI. The association with SHBG was stronger in men with a
lower BMI (P for interaction = 0.03). Associations with TT and
FT were not modified by BMI. We also observed a significant
interaction with age. Associations of TT and FT with MetS were
stronger in men aged ,40 years (P for interaction = 0.004 and
0.01 respectively).
Associations between sex hormones and incident MetS
In total, 584 incident MetS cases were documented during
17,625 person years of follow-up. Men with low sex hormone
concentrations at baseline had an increased risk of incident MetS
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at follow-up (Table 4). HRs per quartile decrease were 1.24 (95%
CI 1.16-1.35), 1.43, (95% CI 1.29-1.59) and 1.14 (95% CI 1.01-
1.29) for TT, SHBG and FT respectively. Again, adjustment for
lifestyle factors had little effect, but associations weakened after
further adjustment for BMI and HOMA-IR. In particular,
associations for FT were no longer significant after adjustment
for BMI (Table 4). The association with TT was attenuated, but
remained significant after adjustment for SHBG (HR per quartile
decrease of TT =1.13 (95% CI 1.01-1.27)).
Interaction analyses showed that the association between TT
and MetS was strongest in men with a BMI ,25 kg/m2 (Table 5,
P for interaction = 0.02). Although no signification interaction
between SHBG and BMI was observed, there was some evidence
of a U-shaped relation with associations being strongest in men ,
25 kg/m2 (Table 5). In contrast to the cross-sectional data, no
effect modification by age was observed in prospective analyses.
We repeated all analyses first, using non-fasting blood samples
and second, after excluding men with a history of type 2 diabetes
and CVD. Estimates were not materially different in these
sensitivity analyses. Results remained also unchanged in analyses
using study-specific quartiles and analyses restricted to population-
based samples (data not shown).
Associations between sex hormones and number of
MetS components
Figure 1 shows the mean concentrations of TT, SHBG, and FT
according to the number of MetS components. In cross-sectional
analyses, TT, SHBG, and FT concentrations decreased gradually
with increasing number of prevalent MetS components (P trend ,
0.001). Although differences in sex hormone concentrations were
smaller for incident MetS components, a gradual linear decrease
of TT, SHBG, and FT was observed as the number of components
increased (Figure 1).
Associations between sex hormones and individual MetS
components
Figure 2 shows the multivariable-adjusted ORs for each
prevalent MetS component. Associations with TT were strongest
for prevalent abdominal obesity (OR per quartile decrease = 1.58
(95% CI 1.51-1.66)) and hypertriglyceridemia (OR per quartile
decrease = 1.57 (95% CI 1.50-1.65)), and weakest for prevalent
hypertension (OR per quartile decrease = 1.24 (95% CI 1.18-
1.31)). A similar pattern was observed for SHBG and FT, with the
exception that low FT and SHBG concentrations were also
strongly linked to prevalent hyperglycaemia (Figure 2).
Differences in strength were less marked for incident MetS
components, although a similar pattern for TT was observed. Low
TT concentrations at baseline were most strongly associated with
incident abdominal obesity (HR per quartile decrease = 1.19
(95% CI 1.09-1.29)) and hypertriglyceridemia (HR per quartile
decrease = 1.21 (95% CI 1.10-1.34)). Low baseline SHBG
concentrations were associated with all incident MetS compo-
nents. Associations were strongest for incident hyperglycaemia
(HR per quartile decrease = 1.46 (95% CI 1.20-1.77)) and
hypertriglyceridemia (HR per quartile decrease = 1.40 (95% CI
1.23-1.61)). Low FT concentrations were associated with incident
hypertriglyceridemia (HR =1.18 (95% CI 1.01-1.38)) and
abdominal obesity (HR =1.13 (95% CI 0.98-1.29)), although
the latter was not statistically significant.
Discussion
In this unique meta-analysis of individual participant data, we
found that men with low concentrations of TT, SHBG and FT
were more likely to have MetS compared to those having high sex
hormone concentrations. The revealed associations were inde-
pendent of age and lifestyle factors and were weaker for incident
than prevalent MetS. SHBG was the main determinant of incident
Table 3. Odds ratios for prevalent metabolic syndrome per quartile decrease of total testosterone, SHBG and free testosterone,
stratified by age and BMI – results from cross-sectional studies.
OR (95% CI)
Total testosterone SHBG Free testosterone
Body mass index
,25 kg/m2 N= 2377 N= 1688 N=1688
1.43 (1.24–1.65) 2.20 (1.77–2.72) 1.22 (0.97–1.53)
25–30 kg/m2 N= 3969 N= 2714 N=2714
1.51 (1.40–1.62) 1.50 (1.35–1.66) 1.29 (1.16–1.44)
.30 kg/m2 N= 1720 N= 1145 N=1145
1.37 (1.24–1.51) 1.33 (1.18–1.50) 1.31 (1.15–1.50)
P interaction 0.40 0.003 0.67
Age
,40 years N= 1080 N= 875 N=875
1.87 (1.57–2.22) 1.50 (1.22–1.84) 1.57 (1.29–1.91)
40–60 years N= 3985 N= 3185 N=3185
1.78 (1.65–1.92) 1.68 (1.54–1.83) 1.52 (1.38–1.66)
$60 years N= 3029 N= 1492 N=1492
1.54 (1.43–1.66) 1.61 (1.43–1.82) 1.32 (1.16–1.50)
P interaction 0.004 0.11 0.01
Odds ratios are adjusted for age, smoking, alcohol consumption and physical activity. Abbreviations: SHBG = sex hormone-binding globulin; OR = odds ratio; CI =
confidence interval.
doi:10.1371/journal.pone.0100409.t003
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MetS, but adjustment for SHBG did not fully explain associations
of TT with MetS. Associations of testosterone and SHBG with
MetS were strongest in non-overweight men and abdominal
obesity, hypertriglyceridemia and hyperglycaemia were the main
drivers of the overall associations found.
The major strength of our study was that by re-analysing the
individual data from 20 observational studies, we were able to
study relevant subgroups and individual MetS components with
sufficient statistical power. Furthermore, the use of raw data
enabled us to apply consistent methods for MetS assessment and
FT estimation, and to adjust for potential confounders in a
uniform way. Nevertheless, some potential limitations should be
discussed. First, not all eligible studies participated in this
collaborative meta-analysis, which may have introduced ‘collab-
oration bias’, a term equivalent to publication bias in literature-
based meta-analyses. However, we think that reasons to
participate are pragmatic, not related to either determinant or
outcome status, therefore minimizing the likelihood of this bias.
Second, individual studies were methodologically heterogeneous;
confounder and outcome data were not collected in a standardised
way. Our statistical approach accounted for these methodological
differences between studies by incorporating random effects at the
study level. Third, all studies used commercially available
immunoassays for the measurement of testosterone and SHBG.
These assays lack reliability in the lower end of the distribution
[40], but over a wide range of concentrations their measures
correlate well with those obtained with mass spectrometry [41–
45]. Also, the diversity of immunoassays used will not have a major
impact on our risk estimates, since different assays are likely to
classify subjects in the same quartile. Previous studies have shown
that associations with known metabolic determinants do not
heavily depend on the assay being used [45,46]. Moreover,
measurement errors resulting from interlaboratory assay differ-
ences are likely to be random, and may have resulted in
underestimated associations rather than producing spurious ones
[46]. Another limitation is that FT concentrations were not
measured in our study but calculated using the algorithm of
Vermeulen [22]. This algorithm gives a reasonable approximation
of serum FT concentrations in men [22], but the level of
agreement depends on the testosterone and SHBG assay being
used [47]. Therefore, random measurements errors in FT are
expected to be larger due to interlaboratory differences in both TT
and SHBG assays. However, when we repeated the analysis using
study-specific hormone quartiles, results did not change substan-
tially, indicating that assay heterogeneity does not have a major
impact on our findings. Nonetheless, more efforts are needed to
increase the accuracy and standardization of sex hormone
measurements. This is particularly relevant when using hormone
measurements for individual diagnoses and treatment decisions,
which require methods with high accuracy and precision at the
lower end of the distribution. Fourth, twenty-four percent of all
participants had non-fasting blood samples. In our analysis, we
adjusted for fasting state by using sample-specific cut-offs. Since
results were not materially different in analyses excluding non-
fasting samples, we consider differential misclassification due to
fasting state negligible. Finally, sex hormones were measured only
once at baseline in each individual study, precluding us from
studying time-related changes in sex hormone concentrations and
MetS risk.
Notwithstanding the prospective design, we cannot draw
definitive conclusions on the causal directionality of the observed
associations. Stronger associations of sex hormones with prevalent
than incident MetS suggest that low testosterone and SHBG are
merely a result rather than cause of MetS. Indeed, weight loss and
maintenance have been associated with an increase in testosterone
and SHBG concentrations in obese men with MetS [48,49].
Likewise, experimental studies show suppressive effects of adiposity
and insulin resistance on testosterone production in men [50,51].
Table 5. Hazard ratios for incident metabolic syndrome per quartile decrease of total testosterone, SHBG and free testosterone,
stratified by age and BMI – results from prospective studies.
HR (95% CI)
Total testosterone SHBG Free testosterone
Body mass index
,25 kg/m2 N= 1045 N= 625 N=625
1.58 (1.25–2.00) 1.59 (1.15–2.21) 1.16 (0.79–1.69)
25–30 kg/m2 N= 1546 N= 1028 N=1028
1.08 (0.98–1.19) 1.17 (1.03–1.33) 1.09 (0.94–1.26)
$30 kg/m2 N= 342 N= 239 N=239
1.13 (0.95–1.36) 1.49 (1.16–1.93) 1.12 (0.85–1.48)
P interaction 0.02 0.65 0.62
Age
,40 years N= 487 N= 372 N=372
1.24 (1.00–1.53) 1.39 (1.09–1.77) 100 (0.77–1.29)
40–60 years N= 1449 N= 1027 N=1027
1.27 (1.14–1.42) 1.32 (1.15–1.51) 1.22 (1.04–1.43)
$60 years N= 1005 N= 495 N=495
1.19 (1.04–1.35) 1.32 (1.07–1.62) 1.11 (0.87–1.43)
P interaction 0.31 0.53 0.45
Hazard ratios are adjusted for age, smoking, alcohol consumption and physical activity. Abbreviations: SHBG = sex hormone-binding globulin; OR = odds ratio; CI =
confidence interval.
doi:10.1371/journal.pone.0100409.t005
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On the other hand, testosterone and SHBG may also influence
MetS etiology. Polymorphisms in the SHBG gene have been
associated with risk of type 2 diabetes, suggesting a causal role for
SHBG in metabolic disease risk [52,53]. Moreover, a recent meta-
analysis of the few available testosterone supplementation studies
shows that testosterone therapy is associated with a significant
reduction of fasting glucose, HOMA-IR, triglycerides and waist
circumference as well as an increase of HDL-cholesterol [18].
Thus, observational and experimental data point to bidirectional
relationships between sex hormones and MetS.
Adjustment for lifestyle factors had little effect on the observed
associations of TT, SHBG and FT with MetS, but the strength of
associations was nearly halved after adjustment for BMI and
HOMA-IR. The major impact of body composition and insulin
resistance was expected, as both factors represent the core
abnormality of MetS [54]. Hence, adjusting for BMI and
HOMA-IR may represent overadjustment. Consistent with our
literature-based meta-analysis [17], we found an increase in MetS
incidence with lower FT concentrations. Associations with TT and
MetS remained also significant after adjusting for SHBG. These
findings are important because they show that the association
between testosterone and MetS cannot solely be attributed to
SHBG. The fact that previous studies have reported conflicting
results for FT [7–9,14,15,55], might be due to differences in
sample size and handling of potential confounders as described
above. The large sample size of the present pooled meta-analysis
enhanced the statistical power to detect small to moderate
associations between FT and MetS.
Apart from being associated with MetS as an entity, sex
hormones also show an inverse association with the number of
MetS components. Previous data regarding this association are
limited. In the BACH study [9], the largest difference in sex
hormones was found between men having one vs. two MetS
components, suggesting a decline in sex hormone concentrations
before the actual onset of MetS. Our results do not support such a
threshold effect, as all sex hormones decreased gradually with
increasing number of MetS components. Among the five
components, TT was most strongly associated with hypertriglyc-
eridemia and abdominal obesity. A similar pattern was found
previously in cross-sectional studies [7–9,16], but this is the first
study showing such a relationship with incident MetS components.
Apart from hypertriglyceridemia and abdominal obesity, SHBG
and FT were also strongly associated with hyperglycaemia.
Interestingly, we found that the association between TT and
incident MetS was strongest in men with a BMI ,25 kg/m2. The
reason for this interaction is not clear, but the weaker association
in overweight men suggests a dominant role for non-androgenic
risk factors in this specific subgroup. This finding may also indicate
the emergence of relative androgen insensitivity with increasing
BMI. In children an inverse association between BMI and
androgen receptor sensitivity has been reported [56], but no
studies so far have explored this association in middle-aged and
older men. Cross-sectionally, we found that SHBG was more
strongly associated with prevalent MetS in men with a lower BMI.
However, a clear interaction with BMI could not be confirmed for
incident MetS. Previously, a subgroup effect of BMI has been
demonstrated in relation to leptin [57], with associations of SHBG
Figure 1. Sex hormone concentrations by number of prevalent and incident metabolic syndrome components – results from cross-
sectional and prospective studies. Multivariable adjusted means and 95% confidence intervals for sex hormone concentrations by number of
prevalent and incident metabolic syndrome components and the P value for linear trend. Abbreviations: SHBG = sex hormone-binding globulin.
Means are adjusted for age, smoking, alcohol consumption and physical activity.
doi:10.1371/journal.pone.0100409.g001
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and FT being absent in obese men. Leptin resistance becomes
more prevalent with increasing BMI [58], providing an explana-
tion for the weaker associations found in overweight men. Another
explanation for the observed interactions with BMI is the higher
imprecision of hormone assays toward the lower end of the
hormone distribution. Testosterone and SHBG concentrations
decrease with increasing BMI and associations may thus be more
difficult to detect in subgroups of overweight and obese men. We
also found an interaction between testosterone and age when
analyzing prevalent MetS, but this interaction could not be
confirmed for incident MetS.
In conclusion, we observed a robust, dose-response relationship
of low testosterone and SHBG concentrations with prevalent and
incident MetS in men, with associations being primarily mediated
Figure 2. Odds ratios and hazard ratios for individual metabolic syndrome components per quartile decrease of total testosterone,
SHBG and free testosterone. Models are adjusted for age, smoking, alcohol consumption and physical activity. Abbreviations: SHBG = sex
hormone-binding globulin; OR = odds ratio; HR = hazard ratio; CI = confidence interval.
doi:10.1371/journal.pone.0100409.g002
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through abdominal obesity, hypertriglyceridemia and hypergly-
caemia. The weaker associations observed in overweight men
warrant further investigation as this specific subgroup may
represent a target for future prevention and intervention.
Altogether, these findings provide more insight into the biological
mechanisms linking low testosterone and SHBG to MetS.
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